Based on the Santen Pharmaceutical Co stock forecast from 0 analysts, the average analyst target price for Santen Pharmaceutical Co is not available over the next 12 months. Santen Pharmaceutical Co’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Santen Pharmaceutical Co is Very Bearish, which is based on 0 positive signals and 6 negative signals. At the last closing, Santen Pharmaceutical Co’s stock price was USD 10.74. Santen Pharmaceutical Co’s stock price has changed by +6.65% over the past week, +6.44% over the past month and +4.60% over the last year.
No recent analyst target price found for Santen Pharmaceutical Co
No recent average analyst rating found for Santen Pharmaceutical Co
Company Overview Santen Pharmaceutical Co
N/A
N/A
N/A
N/A
USD
USA
Adjusted Closing Price for Santen Pharmaceutical Co (SNPHY)
Loading...
Unadjusted Closing Price for Santen Pharmaceutical Co (SNPHY)
Loading...
Share Trading Volume for Santen Pharmaceutical Co Shares
Loading...
Compare Performance of Santen Pharmaceutical Co Shares
Frequently Asked Questions About Santen Pharmaceutical Co (SNPHY) Stock
Stock Target Advisor's fundamental analysis for Santen Pharmaceutical Co's stock is Very Bearish.
Unfortunately we do not have enough data on SNPHY's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on SNPHY's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on SNPHY's stock to indicate if its overvalued.
The last closing price of SNPHY's stock was USD 10.74.
Unfortunately we do not currently have any market capitalization data for SNPHY's stock.
Unfortunately we do not have enough analyst data on SNPHY's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Santen Pharmaceutical Co's stock.
Sorry, we do not have any data on the number of employees for Santen Pharmaceutical Co.
Sorry we do not have any infomation available on Santen Pharmaceutical Co's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Santen Pharmaceutical Co (SNPHY) Stock
Stock Target Advisor's fundamental analysis for Santen Pharmaceutical Co's stock is Very Bearish.
Unfortunately we do not have enough data on SNPHY's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on SNPHY's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on SNPHY's stock to indicate if its overvalued.
The last closing price of SNPHY's stock was USD 10.74.
Unfortunately we do not currently have any market capitalization data for SNPHY's stock.
Unfortunately we do not have enough analyst data on SNPHY's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Santen Pharmaceutical Co's stock.
Sorry, we do not have any data on the number of employees for Santen Pharmaceutical Co.
Sorry we do not have any infomation available on Santen Pharmaceutical Co's address.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SNPHY !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
